オクラホマにおける子宮内膜がんの臨床試験
オクラホマ内の拠点で、子宮内膜がんに関する28件の研究が参加者を募集しています。
オクラホマ内の都市
公式研究テキスト（英語）
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
- University of Oklahoma Health Sciences Center, Oklahoma City
被験者募集中第2相
全年齢 · 全性別 · 2026/10/02更新 · NCT05564377Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial Cancer
- University of Oklahoma Health Sciences Center, Oklahoma City
被験者募集中第1相
18歳以上 · 女性 · 2026/10/02更新 · NCT05950464The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
- University of Oklahoma, Oklahoma City
被験者募集中第1/2相
12歳以上 · 全性別 · 2026/10/02更新 · NCT04585750Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer
- University of Oklahoma Health Sciences Center, Oklahoma City
被験者募集中第3相
18歳以上 · 女性 · 2026/10/02更新 · NCT07198074Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma
- University of Oklahoma Health Sciences Center, Oklahoma City
被験者募集中第2相
18歳以上 · 女性 · 2026/09/28更新 · NCT05112601Study of AVZO-021 in Patients With Advanced Solid Tumors
- Avenzo Therapeutics Recruiting Site, Oklahoma City
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/28更新 · NCT05867251Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers
- Stephenson Cancer Center, Oklahoma City
被験者募集中第1/2相
18歳以上 · 女性 · 2026/09/25更新 · NCT03564340Adjuvant Therapy in POLE-Mutated and p53-Wildtype/NSMP Early Stage Endometrial Cancer RAINBO BLUE & TAPER
- University of Oklahoma Health Sciences Center, Oklahoma City
被験者募集中第2相
18歳以上 · 女性 · 2026/09/24更新 · NCT05640999Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
- University of Oklahoma, Oklahoma City
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/22更新 · NCT06128551A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)
- Oklahoma Cancer Specialists and Research Institute, LLC ( Site 6047), Tulsa
被験者募集中第3相
18歳以上 · 女性 · 2026/09/17更新 · NCT06952504A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer
- Peggy & Charles Stephenson Oklahoma Cancer Center, Oklahoma City
被験者募集中第3相
18歳以上 · 女性 · 2026/09/17更新 · NCT06340568DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer
- Research Site, Oklahoma City
被験者募集中第3相
18歳以上 · 女性 · 2026/09/03更新 · NCT06989112Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors
- OU Health Stephenson Cancer Center, Oklahoma City
被験者募集中第1相
15歳以上 · 全性別 · 2026/08/25更新 · NCT06276491A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma
- Stephenson Cancer Center at OU Health, Oklahoma City
被験者募集中第2相
18歳以上 · 女性 · 2026/08/21更新 · NCT05548296A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
- Normunity Investigational Site, Oklahoma City
被験者募集中第1相
18歳以上 · 全性別 · 2026/08/18更新 · NCT07182149A Study of DM002 in Patients With Advanced Solid Tumors
- University of Oklahoma Health Sciences Center, Oklahoma City
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/08/07更新 · NCT06751329Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
- University of Oklahoma - Health Sciences Center, Oklahoma City
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/08/04更新 · NCT05579366A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
- Stephenson Cancer Center, Oklahoma City
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/07/30更新 · NCT04657068Predicting Response to Immunotherapy From Analysis of Live Tumor Biopsies (ELEPHAS-05)
- Mercy Hospital - OKC, Oklahoma City
被験者募集中観察研究
18歳以上 · 全性別 · 2026/06/29更新 · NCT07327489A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
- Stephenson Cancer Center Oklahoma University Health, Oklahoma City
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/06/29更新 · NCT05377996A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial Cancer
- University of Oklahoma Health Stephenson Cancer Center, Oklahoma City
被験者募集中第1/2相
18歳以上 · 女性 · 2026/04/01更新 · NCT04486352Uterine Preservation Via Lifestyle Transformation
- University of Oklahoma, Oklahoma City
被験者募集中第2相
18歳以上 · 女性 · 2026/01/20更新 · NCT05903131A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas
- Dren Investigational Site, Oklahoma City
被験者募集中第1相
18歳以上 · 全性別 · 2026/01/07更新 · NCT06999187Zanzalintinib in Combination With Paclitaxel in Recurrent High Grade Uterine Cancer
- University of Oklahoma, Oklahoma City
被験者募集中第1相
18歳以上 · 女性 · 2025/12/11更新 · NCT06795009Trial of Nab-Sirolimus in Combination With Letrozole in Patients With Advanced or Recurrent Endometrioid Endometrial Cancer
- Oklahoma University Stephenson Cancer Center, Oklahoma City
被験者募集中第2相
18歳以上 · 全性別 · 2025/11/13更新 · NCT05997017A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Endometrial Cancer.
- University of Oklahoma, Oklahoma City
被験者募集中第2相
18歳〜70歳 · 女性 · 2025/10/30更新 · NCT06481592SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Tulsa
被験者募集中観察研究
全年齢 · 全性別 · 2025/10/28更新 · NCT03452774Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer
- Oklahoma Cancer Specialists and Research Institute, Tulsa
被験者募集中第2/3相
18歳以上 · 女性 · 2024/05/02更新 · NCT05797831ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。